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Abstract
We develop a simulation tool to support policy-decisions about healthcare for chronic dis-
eases in defined populations. Incident disease-cases are generated in-silico from an age-sex
characterised general population using standard epidemiological approaches. A novel disease-
treatment model then simulates continuous life courses for each patient using discrete event
simulation. Ideally, the discrete event simulation model would be inferred from complete lon-
gitudinal healthcare data via a likelihood or Bayesian approach. Such data is seldom available
for relevant populations, therefore an innovative approach to evidence synthesis is required.
We propose a novel entropy-based approach to fit survival densities. This method provides a
fully flexible way to incorporate the available information, which can be derived from arbitrary
sources. Discrete event simulation then takes place on the fitted model using a competing
hazards framework. The output is then used to help evaluate the potential impacts of policy
options for a given population.
Keywords: Cardiovascular disease; Coronary heart disease; Discrete event simulation; Survival
analysis; Competing hazards; Policy model
1 Introduction
Common chronic diseases, such as cardiovascular diseases, are a major public health problem and
consume large amounts of scarce healthcare resources [1]. In order to use limited healthcare re-
sources to best effect for local populations, there is a need for decision-support tools when consid-
ering different medical and public health approaches to chronic diseases. This is a complex area
beyond the information resources of most healthcare commissioning organisations. So we consider
how commissioners might explore the potential impacts of different policy options via a flexible
and accessible model. In particular, we shall present a coronary heart disease (CHD) simulation
model that is both flexible and useful to commissioners and providers. We build a discrete event
simulation model that accounts for the population evolution over time to better understand the
process behind CHD. Ideally, the model would be inferred from complete longitudinal data for a
relevant population via a likelihood or Bayesian approach. Unfortunately, such data is not readily
available and innovative ways are needed to combine information from different sources. Therefore,
a graph representation and survival analysis methods have been combined with a novel application
of simulated annealing in order to learn the temporally dependent distributions of the model.
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Our work incorporates and extends several aspects of previous chronic disease modelling ap-
proaches. The IMPACT I model [10] was the case study for the model described in this paper. It
is a population-level, spreadsheet-based model using simple epidemiological and economics meth-
ods to estimate the number of deaths prevented or postponed (DPP). The model is theoretically
simple, and has undergone extensive validation, highlighting limitations that gave rise to the work
presented here. Similar to our model, the Weinstein model, [20], is divided into a population health
(primary-side) and a patient disease module (secondary-side). The Weinstein model also includes a
bridge module which controls an individual’s fate in the first 30 days after developing CHD. Despite
being a relatively old, discrete time model, this is one of the more sophisticated in this field. Similar
to the Weinstein model, the CHD Life Expectancy Model considers individuals in discrete time.
It is, however, less sophisticated that the Weinstein model in the sense that there are fewer states
and the time periods are fixed. Closest to our modelling approach is the CHD Policy Analysis
Model [2]. Again, it is divided in to a primary side and a secondary side, with model parameter
estimates derived directly from the literature. The Archimedes model is a micro-simulation model,
which simulates patients to a high level of detail by focusing on the underlying pathophysiological
processes that determine disease [18]. The model has predicted the outcomes of notable clinical
trials well, and has significant potential generalisability. Archimedes is closed proprietary work,
therefore it is not possible to examine the details of the model implementation. This is concerning
given the model complexity and the public health interest involved. An epidemiological review of
CHD policy models is given in [19].
This document is structured as follows. In Section 2, the mathematical preliminaries are given.
Then, in Section 3 we describe how these ideas are used to build the general policy model. Section 4
then specifies a baseline scenario and the context of the paucity of relevant data available. In
Section 5, we explain how the model is fit in light of the data. Section 6 investigates how the model
is modified under certain interventions. Section 7 applies the approach to a specific motivating
CHD example. Finally, Sections 8 and 9 summarise and draw conclusions with ideas for future
work.
2 Background
In this section, we introduce existing theory and define the notation necessary for the subsequent
sections.
Letting T denote event time, a hazard function is defined as a limiting probability,
h(t) = lim
δ↓0
P(t ≤ T ≤ t+ δ|T ≥ t)/δ. (1)
Further, consider collections of competing hazards or causes of failure, indexed by integers 1 to K
and with corresponding latent failure times T1, T2, . . . , TK . The marginal hazard is defined as the
hazard of event k = 1, 2, . . . ,K occurring, ignoring the possibility that another event k′ 6= k may
have occurred first. Suppose that each event has an associated marginal hazard function given by
hk(·), k = 1, . . . ,K. Calculation of the overall hazard assumes independence between the competing
hazards. Specifically, this is, ‘the time of failure from cause k under one set of study conditions
in which all K causes are operative is precisely the same as under an altered set of conditions in
which all causes except the kth have been removed’ [16].
From (1), the marginal hazards are defined as
hk(t) = lim
δ↓0
P(t ≤ Tk ≤ t+ δ|Tk ≥ t)/δ, k = 1, . . . ,K.
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The first failure occurs at time T = mink{Tk; k = 1, . . . ,K}. Let the corresponding cause of failure
at time T be denoted by C = argmink{Tk; k = 1, . . . ,K}. Then, we are interested in the joint
distribution of (T,C).
Note that we do not observe the full set of failure times T1, T2, . . . , TK , we only observe the one
actual failure time T . Therefore, if we had real data, it would not be possible to estimate the model
[16]. In particular, it is impossible to identify the dependence structure from data. On the other
hand, any collection of competing hazards with any dependence structure can be generated from a
related collection of independent competing hazards [8].
A sub-hazard distribution (also known in the literature as a cause-specific hazard) will be of
central importance. The sub-hazard distribution describes the hazard of failing specifically from a
given cause (rather than any of the competing causes). From (1), this is defined as
hsubk (t) = lim
δ↓0
P(t ≤ Tk ≤ t+ δ|T ≥ t)/δ, k = 1, . . . ,K.
Finally, under independence of competing hazards, the overall hazard is given by
h(t) =
K∑
k=1
hsubk (t).
The difference between the sub-hazard and the marginal hazard is that the marginal hazard de-
scribes the failure from a particular cause ignoring any other causes, in contrast to the sub-hazard
which describes the failure from a particular cause rather than any other cause. Under independent
competing hazards, though, these are equal in distribution, hsubk = hk.
In the interest of brevity, for the remainder of this paper, the “sub” superscripts will be sup-
pressed and we will assume reference to the sub-distributions, sub-densities and sub-hazards unless
otherwise stated.
3 Model description
The model is constructed as a graph consisting of edges e ∈ E and vertices v ∈ V , which represents
possible states and transitions between states. We shall fix the vertices (states) and edges (possible
transitions) in advance. The graph is used as a framework for a discrete event simulator such that
for each individual a sequence of events, from a possible set of events defined by the graph, occur
chronologically [3]. The topology of the graph determines that competing risks exist. Further, this
can be thought of as a multi-state model, an extension of the standard competing risks model [15].
Revisiting a previous state is possible, so loops in the graph may exist. A subset of states
are specified as entry states, where an individual has presented with CHD symptoms, and another
(possibly overlapping) subset of states are defined as sink states, corresponding here to death events.
A continuous time multi-state model is developed here, which allows higher fidelity simulation and
more flexible, realistic intervention policies than a discrete time analogue.
3.1 Form of the sub-hazard functions
The hazard functions used in this model are combinations (or mixtures) of L component hazard
functions,
hk(t) =
L∑
i=1
hk,i(t), k = 1, . . . ,K. (2)
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Using a mixture hazard function enables us to better fit the model to data. Different individual
hazard functions may have contrasting properties, so when combined together provide a flexible
distribution. Note that we can even think of the combinations of hazards as competing hazards
themselves. The choice of the number of components in the mixture is part of the model fitting
process.
We shall assume that the mixture hazard function has the proportional hazards property; that
is, multiplying the hazard function by a constant leads to a hazard function of the same form. This
will be exploited when interventions are included in the model.
4 Baseline model
Subsequently, we shall investigate different intervention strategies, but first we produce a baseline
model which describes the current progression or trajectory of each individual. That is, we wish
to describe the patient journeys under existing healthcare protocols. Ideally, we would want to
specify a natural progression baseline model where no healthcare interventions are made. However,
this data is not available since whenever an individual presents with CHD symptoms treatment is
offered and rarely refused.
To determine the model, approximations to the true underlying functions have been produced
from a range of data types from various different sources, and expert elicitation. These approxima-
tions are specified through edge and node constraints which are used in the model fitting process.
In principle, these constraints may be specified on any of the (sub-) distribution, density, hazard or
survival functions. We thus define a generic constraint function φ˜j(tj ,∆j) to include all of these,
where the total number of constraints is N , the constraint index is j = 1, 2, . . . , N , tj is the initial
time and ∆j is the time period.
In practice, the majority of the constraints are specified on the sub-distribution functions. In
this case, we assume that these approximate the transition probabilities, usually with time period
of one year. The transition probabilities essentially constitute a discrete-time Markov jump process.
It is only acceptable to treat transition probabilities as sub-distribution functions if a reasonable
amount of time is spent in each state. To this end, one-year transition probabilities are used in
states that patients are expected to spend a considerable amount of time in, whilst shorter time
periods are used in acute states.
The sub-distribution constraints are usually generated at approximately ten year age intervals.
For example, a constraint may be specified on the transition from state x to y as P(y at age 51 | x at age 50),
with another constraint at P(y at age 61 | x at age 60), and so forth. We shall also assign different
importances to each constraint by allocating a weight wi, i = 1, . . . , N . This weight is designed to
reflect the amount of data, or strength of opinion, upon which a given constraint is based.
5 Model fitting
This section details how the constraints, derived from expert elicitation and data, are used to
approximate underlying continuous functions. This is achieved through a novel application of
simulated annealing and an established entropy measure derived from information theory.
Constraints can be thought of as a list of conditions that we wish the model to satisfy. Define
the generic fitted functions φ̂(t) to be continuous functions on t which assume some parametric
form according to the modelling assumptions. For example, the fitted sub-hazard functions are
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of the form given in (2) and are defined on each edge. A constraint is satisfied exactly when
φ̂j(tj ,∆j) = φ˜
j(tj ,∆j), j = 1, . . . , N . The model fitting procedure is a trade-off between satisfying
a series of constraints, and conforming to a desired model structure. This can be thought of as
a compromise between fit (through the constraints) and avoiding excessive complexity (through
specifying a simple model structure). For flexibility, there are separate models for males and
females, which are fitted separately.
Suppose the fitted values for the constraints computed from the model M are φ̂j(tj ,∆j)(M),
j = 1, . . . , N . The dependence on the model M is explicit here — if we change the model, the fitted
values change also. We are required to specify a model space that we are allowed to work over; call
this model space M, by which we mean
M = {Models in which all edges have a given mixture hazard function
and conform to a fixed graph (V,E)}.
We call a specific model M , so each M ∈ M. The reason that the constraints cannot usually be
satisfied exactly is that the chosen mixture distribution usually has only four free parameters, and
each mixture needs to satisfy more than four constraints.
In the model fitting procedure, we want to find the optimal model M∗, such that the difference
between the supplied and fitted constraints are minimised, i.e.
M∗ =argmin
M∈M
N∑
j=1
wjd
{
φ˜j(tj ,∆j), φ̂
j(tj ,∆j)(M)
}
,
where d is chosen as the Jensen-Shannon distance measure. A simulated annealing algorithm is
used to minimise the given criterion function. The fundamental idea is to change the scale, or
temperature, to allow different moves on the surface of the objective function, thus avoiding being
trapped in local minima [17]. A detailed exposition of this application will appear in a companion
paper.
A step-by-step algorithm description is given in the Appendix.
6 Interventions
An important reason for developing the model was to support the investigation of different in-
tervention strategies in policy scenarios which cannot be feasibly tested in the real world, due to
population, financial, or ethical reasons. The model interventions affect patients indirectly, meaning
that the results of a simulated intervention do not immediately alter the state of an individual but
rather alter the probabilities of entering a given state. That is, an intervention, such as a change
in medical treatment, is designed to alter the disease trajectory of a patient.
The incorporation of an intervention is transparent. A given intervention has proportional
hazards adjustments associated with it for transitions from one state to another. It is an assumption
of the model that the adjustment in the hazard should be proportional. These are incorporated
into the model by simply scaling up or down the marginal hazard function by the relevant amount.
Define this relative risk reduction by η. Each intervention has a given uptake level p, which may
depend on age and gender. Upon entry to a state, an individual receives a given intervention with
probability p.
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For example, suppose that an individual enters state Acute Myocardial Infarction, AMI. Immedi-
ately, we decide whether any of the possible interventions will be applied. Suppose there is only one
intervention to consider, ‘in hospital CPR’. Assume that we have a priori specified the proportion
of the population that has this intervention in this state as p. If the intervention is applied, let
the auxiliary variable r = 1, otherwise r = 0. Thus, sample u ∼ Unif[0, 1] and if u < p then set
r = 1 and apply the intervention, otherwise do not apply the intervention and set r = 0. If we
intervene, then suppose that the specified hazard adjustment factor for a transition AMI → CHD
Death is η = 2/3. Thus, we would have
hnewk (t) =
(
2
3
)r
holdk (t), (3)
for that particular marginal hazard function.
The proportional hazard adjustment depending on a Bernoulli random sample can be thought
of in terms of a frailty model [4], a natural extension to the basic Cox model. The notion of a
frailty model is a convenient way to introduce random effects in to the model. Simply, frailty is
an unobserved random proportionality factor that modifies the hazard function of an individual.
Thus, it is a way of transferring the random selection directly on to the hazard. We do not assume
that the population is homogeneous but rather a heterogeneous sample, where different individuals
have different hazards, in our case either adherent or not.
The univariate frailty model is such that the hazard of an individual depends in addition on
an unobservable random variable Y , which acts multiplicatively on the baseline hazard function.
Analogous to (3),
hnewk (t) = Y h
old
k (t).
In particular, we have the simple case where the relative risk adjustment only takes one of two
values, so setting Z ∼Bernoulli(p) we obtain
hnewk (t) = η
Zholdk (t).
The expect adjusted hazard E[hnewk (t)] = {1 + p(η − 1)}holdk (t). This can be thought of as the
associated proportional adjustment combining the uptake probability and the relative risk. When
the variance Var[hnewk (t)] = {(η − 1)holdk (t)}2p(1 − p), is small or the population size is large then
using E[hnewk (t)] may be more practical whilst not adversely affecting accuracy.
7 Example
In this section, we will give a CHD example implementation with interventions.
7.1 CHD model description
Figure 1 shows the graph structure and Table 1 gives the node descriptions from this graph. For
ease of exposition, we shall assume that both males and females have the same graphical structure.
The graph can be described as follows: Both death states (Non CHD Death and CHD Death) can be
caused by any non-death state. Early Heart Failure (Early HF) can be caused by Unstable Angina
(UA), Chronic Angina (CA) or various stages of Myocardial Infarction (AMI, MI Surv, MI Recur).
Unstable Angina can recur after Acute Myocardial Infarction, which itself can result from either
Chronic Angina or Sudden Death (SD), and so forth.
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Figure 1: Graphical model of the secondary side. This is a multi-state model, where the nodes
represent states that patients can belong to, and the edges represent possible transitions between
the nodes.
Table 1: CVD model node description
Node Name Full Name Description
CA Chronic Angina long term severe chest pain
AMI Acute Myocardial Infarction heart attack
SD Sudden Death heart stopping
MI Surv Myocardial Infarction Survival recovered heart attack
MI Recur Myocardial Infarction Recurrence recurrence of a heart attack
UA Unstable Angina triggered severe chest pain
Early HF Early Heart Failure weak heart
Severe HF Severe Heart Failure very weak heart
Non CHD Death Non CHD Death death by a cause other than CHD
CHD Death CHD Death death caused directly by CHD
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Table 2: Baseline Interventions
Intervention Name States
ACE inhibitors CA, AMI, SD, MI Surv, MI Recur,
UA, Early HF, Severe HF
Aspirin CA, AMI, SD, MI Surv, MI Recur,
UA, Early HF, Severe HF
Aspirin and low molecular weight heparins UA
Glycoprotein IIb/IIIa inhibitors UA
Warfarin CA, MI Surv, MI Recur
Beta blockers in heart failure Early HF, Severe HF
Beta blockers in SP CA, MI Surv, MI Recur
Early beta blockers AMI
In-hospital resuscitation AMI
Out-of-hospital resuscitation SD
Percutaneous coronary intervention (PCI) CA CA
Primary PCI AMI
ST-elevation myocardial infarction (STEMI) PCI UA
Coronary artery bypass graft (CABG) CA
CABG and non-STEMI UA
Primary CABG AMI
Rehabilitation CA, MI Surv, MI Recur, Early HF,
Severe HF
Spironolactone Early HF, Severe HF
Thrombolytics AMI
Statins CA, MI Surv, MI Recur, Early HF,
Severe HF
The baseline model considers a scenario where current guidelines are followed. The interventions
and the related nodes on which they act are given in Table 2.
The percutaneous coronary intervention (PCI), commonly known as coronary angioplasty or
stenting, is a non-surgical way to widen obstructed blood vessels in the heart muscle. Coronary
artery bypass graft (CABG), is surgery that takes arteries or veins from elsewhere in the patient’s
body and uses them to bypass the narrowed blood vessels supplying the heart muscle. Angiotensin-
converting enzyme (ACE) inhibitors are drugs that relax blood vessels and help to decrease blood
pressure. Spironolactone is a drug that gets rid of excess fluid without lowering potassium levels
too much, and helps to reduce blood pressure. Thrombolytics are drugs given just after a heart
attack to dissolve clots in coronary arteries. Statins are drugs that lower cholesterol and help to
slow down the furring up of arteries with fats. Warfarin, heparins and gylyoprotein inhibitors are
drugs that inhibit blood clotting. Beta blockers are drugs that reduce the work of the heart thereby
reducing the risk of angina. Myocardial infarction is heart attack. Rehabilitation is exercise for the
heart muscle to build it up again after a heart attack. Rescuscitation is restarting the heart and
lungs after they have stopped.
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Table 3: Uptake of interventions (%)
State Name ACE Inhibitors Aspirin Beta Blockers Statins
AMI 18 93 4
SD 100
CA 76 93 77 88
MI Surv 76 93 77 88
MI Recur 76 93 100 86
UA 93
Early HF 80 82 62 82
Severe HF 80 82 62 82
Table 4: Risk reductions for ACEI (%)
AMI SD CA MI Surv MI Recur UA Early HF Severe HF CHD Death
AMI 93 93 79
SD
CA 93 93 93 93
MI Surv 80 80 80 80
MI Recur 80 80
UA
Early HF 80 80
Severe HF 80
7.2 Inputs
We will investigate the effect on a population of size 10,000 of different levels of preventative
treatments regimes. The population age structure, gender distribution and starting states are
derived from the well-known ASSIGN cohort [21]. We shall consider 3 separate scenarios: i) no
interventions; ii) beta blockers only iii) statins, beta blockers, aspirin and ACE inhibitors. The
scenarios have been chosen for simplicity of exposition.
Table 3 gives the uptake values on each node for the considered treatments. Tables 4, 5, 6 and 7
give the relative risk reductions on each edge for ACE inhibitors, aspirin, beta blockers and statins
respectively.
7.3 Results
Recall that the model presented in this paper will simulate a given number of individuals until death.
That is, a record is produced of the path that each individual takes through the network with a
list of states visited and times of transition. This information can be manipulated in numerous
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Table 5: Risk reductions for aspirin (%)
AMI SD CA MI Surv MI Recur UA Early HF Severe HF CHD Death
AMI 85 85 85
SD 85 85
CA 85 85 85 85
MI Surv 85 85 85 85
MI Recur 85 85
UA 85 93 85
Early HF 85 85
Severe HF 85
Table 6: Risk reductions for beta blockers (%)
AMI SD CA MI Surv MI Recur UA Early HF Severe HF CHD Death
AMI 96 96 96
SD
CA 77 77 77 77
MI Surv 77 77 77 77
MI Recur 77 80
UA
Early HF 65 65
Severe HF 65
Table 7: Risk reductions for statins (%)
AMI SD CA MI Surv MI Recur UA Early HF Severe HF CHD Death
AMI
SD
CA 78 78
MI Surv 78 78 78 78
MI Recur 78 78
UA
Early HF 78 78
Severe HF 78
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Figure 2: A bar chart showing the number of visits paid to each state during the course of the
scenario when statins, beta blockers, aspirin and ACE inhibitors are all available.
Table 8: Relative risk reductions for the intervention strategies compared against the baseline
simulation
Intervention Relative Risk Reduction p-value
Baseline 0
ACEI 0.101 (0.040) 0.015
Aspirin 0.016 (0.044) 0.710
Beta Blockers 0.137 (0.039) 0.001
Statins 0.115 (0.039) 0.006
ALL 0.356 (0.030) 0.000
different way, some of which are shown here. The type of information and the format in which
it is presented will depend on the particular user. For example, plots of certain output statistics
may be more useful for model development in order to validate and diagnose the model, whereas
other representation may be more useful to policy makers with specific questions and (usually) little
statistical knowledge.
Figures 2, 3, 4 and 5 give possible output presentation for the case where statins, beta blockers,
aspirin and ACE inhibitors are all available. Figures 6, 7, 8 and 9 give some output presentation
for the case where only beta blockers are available. Figures 10, 11, 12 and 13 give possible output
presentation for the case where no interventions are available.
Using a Cox regression approach [4], Table 8 gives relative risk reductions for the intervention
strategies compared against the baseline simulation, where the outcome of interest is time to CHD
death. Relative risk reductions are given, with their standard errors in braces. The p-values
correspond to the null hypothesis that the risk reductions are not different from zero.
If the interventions were acting independently, a Mant-Hicks calculation [13] of the relative risk
reduction expected for the combination of all interventions would be 1−{(1−0.101)× (1−0.016)×
(1− 0.115)} = 0.324. This is well within a 95% confidence interval of the value for all interventions
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Figure 3: A box and whisker plot showing the length of stay in state per visit that an individual
takes in each state when statins, beta blockers, aspirin and ACE inhibitors are all available.
Figure 4: State volume against age when statins, beta blockers, aspirin and ACE inhibitors are all
available.
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Figure 5: Prevalence when statins, beta blockers, aspirin and ACE inhibitors are all available.
Figure 6: A bar chart showing the number of visits paid to each state during the course of the
scenario when only beta blockers are available.
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Figure 7: A box and whisker plot showing the length of stay in state per visit that an individual
takes in each state when only beta blockers are available.
Figure 8: State volume against age when only beta blockers are available.
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Figure 9: Prevalence when only beta blockers are available.
Figure 10: A bar chart showing the number of visits paid to each state during the course of the
scenario with no interventions.
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Figure 11: A box and whisker plot showing the length of stay in state per visit that an individual
takes in each state for the scenario with no interventions.
Figure 12: State volume against age for the scenario with no interventions.
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Figure 13: State prevalence for the scenario with no interventions.
— (0.297, 0.415).
8 Discussion
Figures 2, 6 and 10 show the period prevalence for the full intervention, beta blockers only and
no intervention scenario respectively. It can be seen that the effect of more interventions are to
decrease the number of CHD related deaths and consequently increase the number of non-CHD
related deaths. Also, with the increased amount of preventative treatment, the occurrence of
unstable angina is reduced.
Figures 3, 7 and 11 show the sojourn times at each state visit for the full intervention, beta
blockers only and no intervention scenario respectively. We can see that the length of time in MI
Survival increases with more treatment. This is because patients are less likely to enter an acute
state. Furthermore, the interquartile range for the length of time in state for Early and Severe
Heart Failure and, in particular, MI Survival is greater and with fewer outliers for the treatment
scenarios. This is due to the patients under-going treatment remaining in the model for longer
periods, i.e. reaching an older age, but then they face a steep increase in non-CHD death risk. This
effect is known as shouldering.
Figures 4, 8 and 12 show the state volume against age for the full intervention, beta blockers only
and no intervention scenario respectively. Again, we can see the increase in the number of non-CHD
deaths in the scenarios with more treatments. Note that the Healthy region is identical between
plots since this is the entry state of the model and so not affected by secondary interventions.
Figures 5, 9 and 13 show the period prevalence against age for the full intervention, beta blockers
only and no intervention scenario respectively. The plots show that the period prevalence between
scenarios is quite similar. Is seems that many of the paths followed by the patients are similar
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between scenarios. However, there appear to be more individuals in the chronic angina state for
the full treatment scenario, possibly due to these patients not entering a more serious state.
9 Conclusions
The design of a chronic disease policy model for prognostic reasoning (making a prediction about
what will happen in the future) [12] has been detailed. In particular, a CHD model example has
been presented and example output discussed.
The main features are the following:
• The model is a patient care model which simulates the patient trajectory from the onset of
the disease to death.
• Interventions strategies can be explored both at a population level and an individual level.
• A novel model fitting methodology has been developed to specify a sufficiently accurate model
using historical data and expert judgment.
In particular, the strengths of this model are:
• The model is dynamic in that it represents the patient journey through time. Patient histories
may be utilised to adjust transition probabilities in the future.
• The specification of the model using ‘constraints’ is very flexible. This allows for the inclusion
of prior knowledge in a simple form which is intuitive for practitioners.
• The use of (local) hazard functions admits a powerful and flexible model structure to the
whole model.
• The graphical representation of the discrete event simulator is intuitive for clinicians and
policy makers, thereby making it easier for them to develop models and interpret results.
In order to build the model certain assumptions have been necessary. These are listed below.
• Focussed context : One important point is that, because we only consider CHD patients, we
can only consider the public health burden in isolation, and not the overall public health
burden. This means that caution is needed in interpreting the results of interventions.
• Constraint specification: In the generation of the constraints, there is an assumption made
about the size of the age interval. It is thus assumed that individuals share sufficiently similar
characteristics within these bands to justify pooling them together.
• Model assumptions: The patient life-courses and the adherences to interventions are assumed
to be independent.
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9.1 Future work
The modelling approach presented in this paper is an effectively structured synthesis of evidence in
the absence of relevant individual-level health data. The above method using specified constraints
is just one way of translating the data into a model parameter estimate. If we had access to other
sources of data, it could be incorporated directly or used to estimate some other quantity of interest
for the process, which would mean a different fitness function would be needed (see Section 5).
Note that the constraints have been produced from data but there is no indication currently
of the uncertainties on these estimates, such as upper and lower bounds. In a standard Bayesian
approach, we would place prior distributions on the parameters determining the static transition
probabilities. Then these would be updated in light of the data. Alternatively, we could place priors
on the parameters of the hazard mixture and then update these after seeing the new data. However,
the way to specify such prior distributions is a significant challenge because of the unintuitive
representation for clinicians and decision makers.
Several model extensions could be made in terms of how interventions are applied. Interventions
need not be singular, static events but may change during the time course of the scenario. It is
more realistic to consider the application and cessation of interventions at any time. This could
be after some set amount of time in a state, at different age groups within a state or at particular
years.
Further, adherence to a given intervention may be generalised to consider more complex temporal
patterns. For example, interventions may be halted at times depending on length of stay in state,
age group or particular age, and alternative interventions may be introduced at this time.
The assumption of adherence independence may also be relaxed. For example, it is clearly more
likely that an individual who has had an intervention for a long period is more likely to continue
with another intervention.
Finally, in practice, limitation of funds will restrict the availability of particular interventions.
Health policy scenarios may even be considered in terms of adding or removing a specific amount of
funding from one intervention option to another. So the outputs of this model should be presented
in economic as as well as health terms.
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A Model step-by-step algorithm description
Table 9: Graph setup
Step Description
1 Define graph (V,E) (nodes v ∈ V and edges e ∈ E).
2 Specify model family M.
3 Specify N constraints, φ˜j(tj ,∆j), j = 1, 2, . . . , N .
4 Fit model by selecting the optimal model,
M∗ =argmin
M∈M
∑N
j=1 wjd
(
φ˜j(tj ,∆j), φ̂
j(tj ,∆j)(M)
)
.
Table 10: Simulation without interventions
Step Description
5 Set maximum scenario duration tmax.
6 a) Define initial number of cases S, depending on
the total population size and the duration of the simulation.
b) Define the data for each individual s:
gender, age, start time ts0 and state x
s
0, either from the primary side or a closed cohort.
7 Set case count s = 1.
8 Set transition count i = 0.
9 Generate a transition type C and time T from the competing risks, Rxsi ,
using the sub-hazard functions,
where T = minr{Tr; r = 1, 2, . . . , Rxsi } and C = argminr{Tr; r = 1, 2, . . . , Rxsi }.
10 Set tsi+1 = T and x
s
i+1 = C.
11 If tsi+1 > tmax and s < S then let s = s+ 1 and go to Step 8.
12 If xsi+1 ∈ {CHD Death, Non CHD Death} and s < S then let s = s+ 1 and go to Step 8.
13 Set i = i+ 1 and go to Step 9.
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Table 11: Simulation with interventions
Step Description
14 Specify L intervention types ω1, ω2, . . . , ωL.
15 For each gender λ ∈ {M,F} and node v ∈ V ,
define a set of interventions τλ,v ⊆ {ωl : l = 1, . . . , L}.
16 Specify the probability of adherence depending on intervention, gender and state νλ,vωl .
17 Define relative risk reductions on each edge e ∈ E, associated with each τλ,v by ηλ,vτ .
18 Set maximum scenario duration tmax.
19 a) Define initial number of cases S, depending on
the total population size and the duration of the simulation.
b) Define the data for each individual s:
gender, age, start time ts0 and state x
s
0,
either generated from the pre-clinical model or a closed cohort.
20 Set case count s = 1 and interventions applied to s by the empty set, Ωs = φ.
21 Set transition count i = 0.
22 For each intervention τλ
s,xsi then,
Ωs = {Ωs,ηλ
s,xsi
τ } with probability νλ
s,xsi
τ .
23 Generate a transition type C and time T from the competing risks, Rxsi ,
using the (proportionally adjusted) sub-hazard functions hΩsr (t), r = 1, 2, . . . , Rxsi ,
where T = minr{Tr; r = 1, 2, . . . , Rxsi } and C = argminr{Tr; r = 1, 2, . . . , Rxsi },
24 Set tsi+1 = T and x
s
i+1 = C.
25 If tsi+1 > tmax and s < S then let s = s+ 1 and go to Step 22.
26 If xsi+1 ∈ {CHD Death, Non CHD Death} and s < S then let s = s+ 1 and go to Step 22.
27 Set i = i+ 1 and go to Step 23.
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